This article is written by Christian Tharp, the author of 5 Star Trading.The S&P 500 hit its last all-time high back at the end of 2014, and has chopped lower since.The Nasdaq has fared a bit better over that stretch, but the index still has yet to hit a new bull market high since the end of December.Through this period […]
Four Billionaire Loved Biotech Stocks That Analysts Think Will DoubleAt Billionairesportfolio.com we actively manage a portfolio of the “best ideas” from the world’s best hedge funds, and our members get to follow along.Following the highest conviction trades of the world’s best hedge funds works especially well in the biotech sector. It gives you direct access to the smartest investment minds […]
Four Billionaire Loved Biotech Stocks That Analysts Think Will DoubleAt Billionairesportfolio.com we actively manage a portfolio of the “best ideas” from the world’s best hedge funds, and our members get to follow along.Following the highest conviction trades of the world’s best hedge funds works especially well in the biotech sector. It gives you direct access to the smartest investment minds […]
View the original here –
Deutsche Bank Loves These Small-Cap Biotech Stocks – PTC …
[…]
Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big biotechs […]
NPS CEO: Shire has rare-disease experience
NPS Pharmaceuticals president and CEO Dr. Francois Nader discusses opportunities the potential deal with Shire presents.
Anyone who follows Jim Cramer’s stock picks knows that he loves the biotech sector. Especially NPS Pharmaceuticals, up 45 percent in the past month. Wowzer!On Sunday, Ireland-based Shire PLC agreed to acquire NPS Pharma for an all cash deal of […]
Rumor has it that if the S&P 500 finishes its first five trading days of the year with a gain, then the year in question will — 80 percent of the time — end with a gain as well.Last Thursday’s rally gave the S&P that five-day gain. However, since that day, the market has seen a decent amount of weakness.The […]
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright ©2015 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.
Read this article:
5 Biotech Stocks With Explosive Drug Pipelines | InvestorPlace
[…]
Source:
Sabby Management Buys 3 Biotech Stocks – NeuroMetrix, Inc …
[…]
They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]
